To evaluate the effect of enhanced T cell recruitment through ATR inhibition in a model representing the patient DLBCL immune context, we used primary cell lines derived from patient-derived tumor xenografts (PDXs). This evidence concerns the gene ATR and diffuse large B-cell lymphoma.